Takedas Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in its Phase 3 Crohns Disease Trial

OSAKA Japan&8211;BUSINESS WIRE&8211;Takeda Pharmaceutical Company Limited TSE4502NYSETAK Takeda today announced topline results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous SC formulation o...